Lupin receives EIR from USFDA for its Aurangabad manufacturing facility
May 3, 2024
Source: https://www.lupin.com/lupin-receives-eir-from-us-fda-for-its-aurangabad-manufacturing-facility/
105
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad manufacturing facility.
The inspection was conducted from March 6 to March 15, 2024. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
Nilesh Gupta, Managing Director, Lupin said, “We are pleased to receive the EIR with VAI status from the USFDA as an outcome of the recent inspection of our Aurangabad facility. It is a testament to our commitment to consistently upholding the highest standards of compliance and providing high-quality healthcare solutions to patients worldwide.”
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Yingtai Medical acquires Weiqiang Medical December 21, 2024
- 4 innovative medical devices approved for market launch December 21, 2024
- Once a month, potential “best-in-class” lipid-lowering drugs apply for listing December 21, 2024
- Notice! Xinma Pharmaceutical Recruitment and Procurement Involved in Bribery December 21, 2024
- New weight loss drug, the world’s first cAMP-biased GLP-1 agonist has been submitted for marketing December 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
